Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel, Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize lifescience-based product discovery and development, together with Ben-Gurion University (BGU), a re ...

Exhibit 99.1 EVOGENE LTD. AND ITS SUBSIDIARIES INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | --- | --- | |-------|------------| | | Page | | | F-2 | | | F-3 | | | F-4 - F-5 | | | F-6 - F-7 | | | F-8 - F-19 | Consolidated Interim Statements of Financial Position Consolidated Interim Statements of Profit or Loss Consolidated Interim Statements of Changes in Equity Consolidated Interim Statements of Cash Flows Notes to Consolidated Interim Financial S ...

REHOVOT, Israel, Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary ...

Financial Data and Key Metrics - Total revenues for the first six months of 2024 reached approximately $5.1 million, compared to $1.3 million in the first half of 2023, driven by Casterra's seed supply and Lavie Bio's licensing agreement [6][29] - Q2 2024 revenues were approximately $914,000, up from $654,000 in Q2 2023, primarily due to increased revenues from Lavie Bio [7][30] - Net loss for the first half of 2024 was approximately $9.8 million, a significant improvement from $14.8 million in the same period last year, driven by increased revenues and decreased operating expenses [7][34] - Projected cash usage for 2024, excluding Biomica and Lavie Bio, is approximately $8 million, a 36% decrease from $12.5 million in 2023 [7][29] Business Line Performance - **Casterra**: Received an additional purchase order of $440,000 for castor seeds, with total existing orders amounting to $8.4 million expected to be fulfilled by the end of 2024 [8][14] - **Biomica**: Preliminary Phase 1 trial results for BMC128 showed promising efficacy and safety in treating refractory cancers, with data presented at ASCO 2024 [9][16] - **Lavie Bio**: Expanded its bio-inoculant product Yalos to winter wheat, doubling its market potential, and identified over a dozen novel microbial candidates using its BDD technology platform [9][15] Market and Strategic Direction - The global castor oil market is projected to reach $1.68 billion by 2028, driven by increasing demand for sustainable and renewable resources in bio-based industries [20][22] - Casterra aims to establish itself as a leading provider of sustainable vegetable oil feedstock, particularly for the biofuel sector, leveraging its elite castor seed varieties and advanced cultivation techniques [18][21] - Evogene's AI-driven tech-engines (MicroBoost AI, ChemPass AI, GeneRator AI) are designed to optimize life science product development across various market segments, focusing on efficiency and cost-effectiveness [10][11] Management Commentary on Future Prospects - Management anticipates continued revenue growth in the second half of 2024, driven by Casterra's seed supply and Lavie Bio's product expansion [6][30] - The company is exploring the potential to expand into castor oil production, which could further enhance its market position and revenue streams [27][28] - Evogene's subsidiaries are advancing their pipelines, with significant milestones expected in Q4 2024, particularly in Lavie Bio's field trials and Biomica's clinical development [15][17] Q&A Session Summary Question: What is Casterra's current backlog for 2025, and will oil production be based in Africa or Brazil? - Casterra is working on its 2025 backlog, with details expected in the next analyst call. Oil production is under evaluation, with potential locations in both Africa and Brazil [35][36] Question: Can you provide an update on AgPlenus? - AgPlenus is focused on building a new pipeline, particularly in fungicides, and is collaborating with Bayer and Corteva. Updates are expected in the next quarter [37][38] Question: What is the trajectory of Casterra's castor seed launch in 2H 2024, and what is the current gross margin profile? - Casterra aims to fulfill $8.4 million in seed orders by the end of 2024, with a current production capacity of over 1,000 hectares. Gross margins are high, particularly in seed sales, with potential for further improvement in oil production [40][42] Question: When should we expect material revenue contribution from Yalos? - Yalos is expected to see material growth in sales by 2026, with early adoption in soybean and canola markets starting in 2025 [43][44] Question: What is Evogene's expected cash position by the end of 2024? - Assuming $8.4 million in castor seed revenues, Evogene's cash position is expected to be around $18-19 million by the end of 2024 [46][47]

Conference call and webcast: today, August 22, 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023. Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million. H1 2024 loss $9.8M, down from $14.8M in H1 2023; Q2 2024 loss $6.0 ...

Core Points - Evogene Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days [1][2] - The compliance issue regarding the bid price deficiency is now considered closed by Nasdaq [2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [3] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components such as microbes, small molecules, and genetic elements [4] - Evogene operates through five subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., which are involved in developing microbiome-based therapeutics, ag-biologicals, next-generation ag chemicals, and superior castor seed varieties respectively [4]

Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the second quarter of 2024, on Thursday, August 22, 2024. Later that day, Company management, will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join ...

Mr. Yoash Zohar, CEO of Casterra states: "Current castor yields from the harvest in Brazil show an impressive improvement in our production capabilities. I am very proud of our professional team, which in past months invested, and keeps investing, time and efforts working closely with our subcontractors to ensure the best agricultural practices and crop performance, to produce Casterra's high quality castor seeds. We also expect to see such positive performance in our African territories where the majority ...

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science-based product development through big data and artificial intelligence, aiming to enhance success rates while reducing development time and costs [3][10] - The company operates through five subsidiaries, each leveraging unique tech engines for product development [4][5] Reverse Share Split - A reverse share split at a ratio of 1-for-10 was approved by shareholders and is set to be implemented after market close on July 24, 2024 [10] - Post-split, the number of issued and outstanding Ordinary Shares will decrease from approximately 50,790,000 to about 5,079,000 [4][10] - The company's registered share capital will remain at NIS 3,000,000 but will be divided into 15,000,000 Ordinary Shares with a par value of NIS 0.2 each [4][10] Shareholder Impact - No fractional Ordinary Shares will be issued; fractional shares will be rounded to the nearest whole share, with no cash payments for fractional shares [2] - Proportionate adjustments will be made to the number of shares issuable upon the exercise of outstanding options and Restricted Share Units (RSUs) [2]

Industry Overview - Winter wheat is a crucial crop in North America and globally, contributing significantly to the agricultural economy and food supply, with the US expected to produce about 1.28 billion bushels in 2024, valued between $5-$10 billion annually [1][7] - The US soybean market size is estimated at approximately $56.2 billion in 2024, indicating substantial market potential for agricultural innovations [2] Company Overview - Lavie Bio is focused on enhancing crop productivity and sustainability through its product Yalos™, which has shown improved early vigor, biomass, root and shoot development, nutrient availability, and feed quality in winter wheat during field trials [7][8] - The company aims to expand Yalos™ into other key crops, such as soybean and canola, with ongoing field trials and an expected commercial launch in 2025 [2][8] - Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's MicroBoost AI technology, to discover and develop bio-stimulant and bio-pesticide products [8][9] Strategic Goals - Lavie Bio's strategy includes consistently introducing innovative ag-biological products to the market while expanding existing products to more crops and regions, reinforcing its commitment to advancing agricultural productivity and sustainability globally [8] - The company aims for Yalos™ to become a leading solution for growers in all major field crops, addressing key growth challenges and enhancing plant health and yield [8]